The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Impact of duration of prior cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) therapy on alpelisib (ALP) benefit in patients (pts) with hormone receptor–positive (HR+), human epidermal growth factor receptor-2–negative (HER2–), PIK3CA-mutated advanced breast cancer (ABC) from BYLieve.
 
Stephen K. L. Chia
Honoraria - AstraZeneca; Exact Sciences; Lilly; Merck; Novartis; Pfizer; Roche
Consulting or Advisory Role - Novartis; Roche
Research Funding - AstraZeneca (Inst); Genentech (Inst); Genomic Health (Inst); Novartis (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Roche (Inst)
 
Manuel Ruiz-Borrego
Honoraria - Novartis; pfizer; Roche/Genentech
Consulting or Advisory Role - Puma Biotechnology; Roche
 
Pamela Drullinsky
Research Funding - Novartis (Inst)
 
Dejan Juric
Consulting or Advisory Role - Eisai; EMD Serono; Genentech; Ipsen; MapKure; Novartis; Petra Pharma; Syros Pharmaceuticals; Vibliome Therapeutics
Research Funding - Amgen (Inst); Eisai (Inst); EMD Serono (Inst); Genentech (Inst); Infinity Pharmaceuticals (Inst); InventisBio (Inst); Novartis (Inst); Pfizer (Inst); Placon (Inst); Syros Pharmaceuticals (Inst); Takeda (Inst); Takeda (Inst)
 
Thomas Bachelot
Consulting or Advisory Role - AstraZeneca; MSD Oncology; Novartis; Pfizer; Roche; Seagen
Research Funding - AstraZeneca (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - AstraZeneca; pfizer; Roche
 
Hope S. Rugo
Honoraria - Mylan; Puma Biotechnology
Consulting or Advisory Role - Samsung
Research Funding - AstraZeneca (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Genentech (Inst); Immunomedics (Inst); Lilly (Inst); Macrogenics (Inst); Merck (Inst); Novartis (Inst); OBI Pharma (Inst); Odonate Therapeutics (Inst); Pfizer (Inst); Seagen (Inst); Sermonix Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - AstraZeneca Spain; Daiichi Sankyo; Macrogenics; Merck; Mylan; Novartis; Pfizer
 
Eva M. Ciruelos
Consulting or Advisory Role - AstraZeneca; Lilly; Novartis; Pfizer; Roche
Speakers' Bureau - Lilly; Pfizer; Roche
Travel, Accommodations, Expenses - Pfizer; Roche
 
Florence Lerebours
Consulting or Advisory Role - AstraZeneca; Eisai; Lilly; Pfizer; Pierre Fabre; Roche
Travel, Accommodations, Expenses - Lilly; Novartis; Pfizer; Pierre Fabre; Roche
 
Aleix Prat
Employment - Novartis (I)
Stock and Other Ownership Interests - Reveal Genomics
Honoraria - Amgen; Daiichi Sankyo; Guardant Health; Lilly; MSD Oncology; Novartis; Pfizer; Roche
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; NanoString Technologies (Inst); Novartis; Oncolytics; Pfizer; Puma Biotechnology; Roche
Research Funding - Incyte (Inst); Novartis (Inst); Puma Biotechnology (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - HER2DX filing; PCT/EP2016/080056: HER2 AS A PREDICTOR OF RESPONSE TO DUAL HER2 BLOCKADE IN THE ABSENCE OF CYTOTOXIC THERAPY; WO/2018/096191. Chemoendocrine score (CES) Based on PAM50 for breast cancer with positive hormone receptors with an intermediate risk of recurrence
Travel, Accommodations, Expenses - Daiichi Sankyo
Other Relationship - Oncolytics; Peptomyc
 
Murat Akdere
Employment - Biomarin (I); Novartis; Sanofi (I)
Stock and Other Ownership Interests - Biomarin (I); Novartis
Travel, Accommodations, Expenses - Biomarin (I); Novartis (I); Sanofi (I)
 
Christina Arce
Employment - Novartis
 
Ennan Gu
Employment - Novartis
Travel, Accommodations, Expenses - Novartis
 
Nicholas C. Turner
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Repare Therapeutics; Roche; Taiho Pharmaceutical; Zeno pharmaceuticals
Research Funding - AstraZeneca (Inst); Bio-Rad (Inst); Clovis Oncology (Inst); Guardant Health (Inst); Pfizer (Inst); Roche (Inst)